Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

San Giovanni Rotondo (FG), Italy Clinical Trials

A listing of San Giovanni Rotondo (FG), Italy clinical trials actively recruiting patients volunteers.

RESULTS

Found (85) clinical trials

A Phase III Multicenter Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)

This is a Phase III, multicenter, open-label, randomized and controlled study to compare the efficacy of a consolidation therapy with RIT vs. ASCT in patients with FL in CR or PR after second or third line chemotherapy supplemented with rituximab. Patients with FL will be eligible for screening at the ...

Phase

0.0 miles

Learn More »

Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy

The study aim is to evaluate the toxicity and activity of a therapeutic approach to high doses with support of peripheral blood stem cells (PBSC) in patients aged 65 and 75 years, chemosensitive relapsed or refractory to therapy first line in terms of event free survival (EFS) and treatment related ...

Phase

0.0 miles

Learn More »

Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas

Adrenal incidentalomas are unsuspected adrenal masses found during abdominal imaging. With the widespread use of computed tomography and MRI, adrenal incidentalomas are found in approximately 2% of patients. In an endocrinology setting, the majority of these masses are benign adenomas of the adrenal cortex. Approximately 10% of these adenomas display ...

Phase N/A

0.0 miles

Learn More »

"AIDA" Protocol (LAP 0493)

The main purposes of the AIDA protocol are to test the role of intermittent maintenance therapy with ATRA, standard maintenance chemotherapy with methotrexate and 6-mercaptopurine of both in PCR negative patients at the end of the consolidation phase and to evaluate the role of allogeneic or autologous bone marrow transplantation ...

Phase N/A

0.0 miles

Learn More »

Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib

Follow-up is required until the end of treatment for the purposes of the study for all patients by standard hematologic, cytogenetic and molecular criteria. This study will not contemplate any additional expense beyond what is expected for a regular follow-up, according to the international guidelines for CML. Sample Size: target ...

Phase N/A

0.0 miles

Learn More »

T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma

Peripheral T-cell lymphomas (PTCLs) comprise a heterogeneous group of neoplasms that are derived from post-thymic lymphoid cells at different stages of differentiation with different morphological patterns, phenotypes, and clinical presentations. PTCLs are highly diverse, reflecting the diverse cells from which they can originate. Peripheral T-Cell Lymphomas account for 5-10% of ...

Phase N/A

0.0 miles

Learn More »

AML Treatment in Untreated Adult Patients

GIMEMA treatment for adult (15-60 yrs) AML patients included a 3-drug induction cycle with DNR (50 mg/m2 d 1, 3, 5), cytarabine (100 mg/m2 d1-10), etoposide (100 mg/m2 d1-5) followed by an intensive consolidation with cytarabine (500 mg/m2/q12 hrs d1-d6) and the same anthracycline as in induction on d 4-6. ...

Phase N/A

0.0 miles

Learn More »

The Hepatitis Delta International Network

The hepatitis international network cohort is a multicenter, observational study that will build up a research registry of HDV patients all over the world. The aims of this project are: i. Collect clinical information from hepatitis delta patients from multiple centers distributed worldwide in order to build up a large ...

Phase N/A

0.0 miles

Learn More »

High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

In this protocol the term high-risk neuroblastoma refers to children with either disseminated disease (INSS stage 4: about 40 to 50% of all neuroblastoma) over the age of one or INSS stage 2 and 3 disease with amplification of the MycN proto-oncogene Between 10% and 20% of children with stage ...

Phase

0.0 miles

Learn More »

European Low and Intermediate Risk Neuroblastoma Protocol

LOW RISK STUDY The low risk group of patients includes NB patients without MYCN amplification with or without life threatening symptoms in the following clinical situations: Children aged 18 months with localised neuroblastoma associated with image defined risk factors precluding upfront surgery (stage INRG L2). Children aged 12 months with ...

Phase

0.0 miles

Learn More »